Castle Biosciences (CSTL) Total Non-Current Liabilities (2018 - 2026)

Castle Biosciences has reported Total Non-Current Liabilities for 9 years, with the latest figure at $91.1 million in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 4.94% year-over-year to $91.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $91.1 million (up 4.94% YoY) and the FY2025 annual result came in at $106.2 million, up 40.83% from the prior year.
• Total Non-Current Liabilities improved to $91.1 million in Q2 2026 per CSTL's latest filing, from $84.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $106.2 million in Q4 2025 and troughed at $34.8 million in Q2 2022.
• A 5-year average of $65.0 million and a median of $62.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 151.53% in 2022, then dropped 11.28% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $48.1 million in 2022, then increased by 29.08% to $62.1 million in 2023, then gained by 21.47% to $75.4 million in 2024, then jumped by 40.83% to $106.2 million in 2025, then declined by 14.16% to $91.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $91.1 million, $84.9 million, and $106.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.